Business
MediPharm Cautions Shareholders To Await Final Results of Annual and Special Meeting
TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: ...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"MediPharm Cautions Shareholders To Await Final Results of Annual and Special Meeting\n\n\n\n TORONTO, June 16, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“\n \n MediPharm\n \n ” or the “\n \n Company\n \n ”), a pharmaceutical company specialized in precision-based cannabinoids, wishes to respond to a misleading press release published earlier today by Apollo Technology Capital Corporation (“\n \n Apollo\n \n ”) prematurely claiming that it considers the results of the annual and special meeting of shareholders scheduled to take place at 3:00 p.m. today (the “\n \n Meeting\n \n ”) to be a clear victory for Apollo.\n \n\n MediPharm wishes to assure its shareholders that as the Meeting has not yet taken place, the results are not yet available. MediPharm will announce the final results of the Meeting in the ordinary course as is required by law and the rules of the Toronto Stock Exchange.\n \n\n\n About\n \n\n MediPharm\n \n\n Labs\n \n\n\n Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.\n \n\n In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company’s current foreign drug manufacturing site registration with the US FDA.\n \n\n In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm’s reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Ger...